SK Pharmteco Partners with NIH and Axle Informatics on Rare Disease Gene Therapy

Event summary

  • SK Pharmteco announced a strategic partnership with Axle Informatics and the NIH to advance rare disease gene therapy programs, focusing on viral vector programs.
  • The collaboration aims to accelerate the translation of academic research into clinical practice, leveraging SK Pharmteco’s manufacturing capabilities and NIH’s research expertise.
  • The inaugural program targets the production of lentiviral vectors (LVV) for treating rare inherited blood and metabolic disorders.
  • SK Pharmteco manufactured drug substance for ex vivo transduction of patients’ CD34+ hematopoietic stem cells and managed batch-release testing in-house.
  • The partnership was funded in part by the National Institutes of Health.

The big picture

This partnership underscores SK Pharmteco’s strategic pivot towards supporting rare disease innovators through specialized viral vector development and manufacturing. The collaboration with the NIH and Axle Informatics highlights the growing trend of public-private partnerships aimed at accelerating the development of complex therapies. By providing comprehensive development and manufacturing solutions, SK Pharmteco positions itself as a critical player in bridging the gap between academic research and clinical practice.

What we're watching

Execution Risk
How SK Pharmteco’s ability to manage batch-release testing and manufacturing will impact the pace of clinical translation.
Strategic Alignment
Whether the partnership can sustain long-term collaboration between academic research and commercial manufacturing.
Market Positioning
The extent to which this collaboration strengthens SK Pharmteco’s role as a key technical partner in the rare disease sector.

Related topics

Partnership